PubMed · 2015 · 34 citations · 32 references
Open access
MedicineOphthalmologyPharmacotherapyAnterior Segment DiseaseOcular DiseaseOphthalmic SurgeryAge-related Macular DegenerationAngiogenesisDiabetic RetinopathyMacular DegenerationMacular DiseaseRetinal Vascular DiseaseAnti-vegf Ocular TherapyMacular Edema TreatmentMacular NeovascularizationPostoperative Visual AcuityRetinal Vein Occlusion TherapyVascular Endothelial Growth FactorVascular Endothelial Growth Factor InhibitionVascular Endothelial Growth Factor Inhibitors
The purpose of this systemic review was to investigate the indications of anti-vascular endothelial growth factor (anti-VEGF) in the treatment of ocular diseases. For this, a comprehensive literature research was performed exploring the current use of anti-VEGF in a variety of retinal or anterior segment diseases and highlighting the visual outcome for these patients. The anti-VEGF therapy is now commonly used for a wide range of pathologies like age-related macular degeneration, retinal vein occlusion or diabetic retinopathy. Pathological processes such as abnormal neovascularization, ocular angiogenesis and macular edema which can greatly reduce visual acuity are now targeted by anti-VEGF treatment, having a major impact on vision.
32
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier et al. · New England Journal of Medicine · 2006 · 5.9K citations · Full text
Medicine, Ophthalmology, Surgery +12
Stefano De Cillà, Serena Farruggio, Stela Vujosevic et al. · Cellular Physiology and Biochemistry · 2017 · 5.1K citations · Full text
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Daniel Martín, Maureen G. Maguire, Stuart L. Fine et al. · Ophthalmology · 2012 · 1.7K citations · Full text